Parallax Volatility Advisers, L.P. Ligand Pharmaceuticals Inc Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $110,061 - $148,026	-1,039 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $130,798 - $277,300	1,019 Added 5095.0%	1,039 $141,000
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $6,335 - $8,234	-30 Reduced 60.0%	20 $5,000
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $7,538 - $10,399	50 New	50 $10,000
Q1 2018 May 15, 2018	SELL	$138.63 - $182.62 $1.12 Million - $1.48 Million	-8,101 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $62,126 - $71,167	-484 Reduced 5.64%	8,101 $1.11 Million
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $1.04 Million - $1.18 Million	8,585	8,585 $1.17 Million

262

18M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.94B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.